¼¼°èÀÇ ÀÓ»ó½ÃÇè½Ã¼³ ¼±Á¤, ½ÇÇö °¡´É¼º Æò°¡, ¿î¿µ, ½Ã¼³ °ü¸®
COUNTRY SELECTION, SITE SELECTION AND STUDY PLANNING CONSIDERATIONS
-±¹°¡ ¼±Á¤, ÀÓ»ó½ÃÇè½Ã¼³ ¼±Á¤ ¹× ÀÓ»ó½ÃÇè °èȹ °ËÅä-
Optimizing Protocol Development and Site Selection: Getting it Right in the Beginning
Joseph Kim, M.B.A., Clinical Operations Director, Shire
Driving Innovation in Study Start-Up: Optimizing Site Performance through Evidence-Based Site Selection
Daphne Van, Global Trial Optimisation Manager, Centre for Project & Study Excellence, GlaxoSmithKline
Co-Presentation
Modeling the Country and Site Selection for Shortening the Clinical Development Timeline
Feng Li, Manager, Stakeholders Office, sanofi-aventis
Jaap Hoek, Vice President, Clinical Sciences & Operations, sanofi-aventis
OPTIMIZING THE FEASIBILITY PROCESS
-½ÇÇö °¡´É¼º Æò°¡ ÇÁ·Î¼¼½ºÀÇ ÃÖÀûÈ-
Importance of Site Feasibility Process: First Critical Step to a Successful Study Outcome
Sudeesh Tantry, Ph.D., Associate Director, Clinical Research, Teva Branded Pharmaceutical Products R&D, Inc.
Co-Presentation
A Collaborative Approach Looking at Feasibility: Plans to Reduce Time, Cost and Percentage of Non-Active Sites from Both the Sponsor and Site Perspective
Nye Pelton, Clinical Operations Portfolio Management, (COPM)USMD, Eli Lilly
Deena Bernstein, Director, Clinical Research, Sheridan Clinical Research
OVERCOMING CHALLENGES IN CLINICAL OPERATIONS,
SITE MANAGEMENT AND RETENTION
-ÀÓ»ó½ÃÇè ¿î¿µ, ÀÓ»ó½ÃÇè½Ã¼³ °ü¸® ¹× È®º¸ÀÇ °úÁ¦ ±Øº¹-
Understanding and Planning for the Increased Incidence of Non-Compliant Patients, Inappropriate Patients and Financially Motivated Patients
Ellis Wilson, Senior Director, Project Coordination, AstraZeneca
Improving Performance and Relationships with International Investigative Sites: Evaluating Relationships with Sponsors and CROs and Vice Versa
Joan Chambers, COO, CenterWatch
Sponsored by
TalkTitle to Be Announced
Trifecta (Speaker to be Announced)
Improving Operational Efficiencies within the Sponsor Organization: A Device Perspective
Kathi Durdon, Manager, Clinical Operations, Welch Allyn
OPERATIONAL CHALLENGES IN PHASE IIIb-IV
-Phase III-IVÀÇ ¿î¿µ»ó °úÁ¦-
Shared Session with Managing Post-Marketing Studies (Phase IIIb-IV) and Registries
Sponsored by
When Enrollment is the True Priority, Which Feasibility, Site Selection and Site Support Methods Apply Equally in Registration and Post-Approval Studies?
Jaime Cohen, Strategic Planning, BBK Worldwide
Unique Challenges of Site Management, Project Management and Ops in Post-Marketing Studies
Speaker to be Announced
Sponsored by
Is There Patient Recruitment in a Post-Marketing Study?
Tess Drahzal, Associate Director, Patient and Physician Services, United BioSource Corporation (UBC)
Operational and Organizational Challenges of Post-Marketing Requirements
Speaker to be Announced
BREAKOUT DISCUSSION GROUPS Interactive Breakout Discussion Groups: Concurrent breakout discussion groups are interactive, guided discussions hosted by a facilitator or set of co-facilitators to discuss some of the more poignant questions facing the industry. Delegates will join a table of interest to them and become an active part of the discussion at hand. It is an informal, yet informative, format that allows attendees to learn from each other and make some new contacts. To get the most out of this interactive format please come prepared to: share examples from your work, vet some ideas with your peers, be a part of group interrogation and problem solving, and, most importantly, participate in active idea sharing. Topics may include:
|
Ãßõ ¿ù¿äÀÏ ¿ÀÈÄ ¼îÆ®ÄÚ½º |






